AnaptysBio, Inc.ANAB stock score: 69/100
$47.40 · +0.72% · Scored Nov 19, 2026
- Technical
- 55
- Fundamental
- 72
- News
- 55
The reading
AnaptysBio (ANAB) scores 69 out of 100, which reads bullish, higher than 96% of Healthcare stocks and 97% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 72, technicals 55.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while EV/EBITDA at 0 weighs the most against it.
On the daily chart, trend-following indicators average 48 and contrarian oscillators 58.
News sentiment is neutral at 55; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 51 to 71, and it is up 14 points over the period.
About AnaptysBio
AnaptysBio (ANAB), also known as Anaptys, is a royalty company that holds financial interests in medicines developed by larger drug makers. It was formerly an antibody research company, but it spun off its drug development operations into a separate company, First Tracks Biotherapeutics, and kept the royalty assets. Its main asset is its share of sales of Jemperli, a PD-1 cancer immunotherapy marketed by GSK and used mainly in endometrial cancer, from which Anaptys receives tiered royalties and milestone payments that rise as annual sales grow. It also holds economics in imsidolimab, an antibody for generalized pustular psoriasis that it licensed to Vanda Pharmaceuticals. Because its revenue comes almost entirely from these agreements, its results track the commercial performance of partner products rather than its own sales efforts.
Jemperli competes with other PD-1 and PD-L1 drugs, including Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, while Anaptys competes for investor capital with royalty holders such as Royalty Pharma and Ligand. Its edge rests on a royalty stream with rising rates at higher sales levels and a lean cost structure after the separation. Investors who follow ANAB stock tend to watch Jemperli sales reported by GSK and new approvals that widen its use. The company’s legal dispute with GSK over the collaboration is closely followed. Imsidolimab’s progress, capital returns to shareholders and any new royalty acquisitions are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward ANAB’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
72Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
EV/EBITDA compares the whole company's value, debt included, with its operating earnings before depreciation.
Price-to-Sales ratio compares market capitalization to annual revenue.
Price-to-Book ratio compares market value to book value.
36 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical · daily
48Pulling it up
The price change over the last 52 weeks.
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.
Holding it back
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Where the close sits against its 100-day SMA.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 55
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 56 | 1 |
| Daily | 48 | 3 |
| Weekly | 54 | 2 |
| Monthly | 67 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 69 |
| Nov 18, 2026 | 68 |
| Nov 17, 2026 | 67 |
| Nov 16, 2026 | 66 |
| Nov 15, 2026 | 67 |
| Nov 14, 2026 | 66 |
| Nov 13, 2026 | 66 |
| Nov 12, 2026 | 71 |
| Nov 11, 2026 | 68 |
| Nov 10, 2026 | 67 |
| Nov 8, 2026 | 63 |
| Nov 7, 2026 | 63 |
| Nov 6, 2026 | 63 |
| Nov 5, 2026 | 63 |
| Nov 4, 2026 | 65 |
| Nov 3, 2026 | 66 |
| Nov 2, 2026 | 65 |
| Nov 1, 2026 | 65 |
| Oct 31, 2026 | 65 |
| Oct 30, 2026 | 65 |
| Oct 29, 2026 | 66 |
| Oct 28, 2026 | 68 |
| Oct 27, 2026 | 67 |
| Oct 26, 2026 | 67 |
| Oct 25, 2026 | 66 |
| Oct 24, 2026 | 66 |
| Oct 23, 2026 | 66 |
| Oct 22, 2026 | 66 |
| Oct 21, 2026 | 66 |
| Oct 20, 2026 | 64 |
| Oct 19, 2026 | 67 |
| Oct 18, 2026 | 65 |
| Oct 17, 2026 | 65 |
| Oct 16, 2026 | 65 |
| Oct 15, 2026 | 67 |
| Oct 14, 2026 | 65 |
| Oct 13, 2026 | 64 |
| Oct 12, 2026 | 65 |
| Oct 11, 2026 | 64 |
| Oct 10, 2026 | 64 |
| Oct 9, 2026 | 64 |
| Oct 8, 2026 | 64 |
| Oct 7, 2026 | 63 |
| Oct 6, 2026 | 65 |
| Oct 5, 2026 | 66 |
| Oct 4, 2026 | 65 |
| Oct 3, 2026 | 65 |
| Oct 2, 2026 | 65 |
| Oct 1, 2026 | 64 |
| Sep 30, 2026 | 66 |
| Sep 29, 2026 | 66 |
| Sep 28, 2026 | 66 |
| Sep 27, 2026 | 55 |
| Sep 26, 2026 | 55 |
| Sep 25, 2026 | 55 |
| Sep 24, 2026 | 56 |
| Sep 23, 2026 | 56 |
| Sep 22, 2026 | 53 |
| Sep 21, 2026 | 55 |
| Sep 20, 2026 | 53 |
| Sep 19, 2026 | 53 |
| Sep 18, 2026 | 53 |
| Sep 17, 2026 | 53 |
| Sep 16, 2026 | 52 |
| Sep 15, 2026 | 52 |
| Sep 14, 2026 | 51 |
| Sep 13, 2026 | 51 |
| Sep 12, 2026 | 51 |
| Sep 11, 2026 | 51 |
| Sep 10, 2026 | 51 |
| Sep 9, 2026 | 52 |
| Sep 8, 2026 | 55 |
| Sep 7, 2026 | 54 |
| Sep 6, 2026 | 54 |
| Sep 5, 2026 | 54 |
| Sep 4, 2026 | 55 |
| Sep 3, 2026 | 56 |
| Sep 2, 2026 | 54 |
| Sep 1, 2026 | 53 |
| Aug 31, 2026 | 53 |
| Aug 30, 2026 | 52 |
| Aug 29, 2026 | 53 |
| Aug 28, 2026 | 53 |
| Aug 27, 2026 | 55 |
| Aug 26, 2026 | 55 |
| Aug 25, 2026 | 56 |
| Aug 24, 2026 | 54 |
| Aug 23, 2026 | 55 |
| Aug 22, 2026 | 55 |
Key facts
- Market cap
- $1.4B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.37
- Risk grade (1–10)
- 7
- Next earnings
- Nov 12, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| MESO Mesoblast | $1.5B | 49 |
| QURE uniQure | $1.4B | 45 |
| ABSI Absci | $1.4B | 27 |
| RAPP Rapport Therapeutics | $1.4B | 32 |
| NBTX Nanobiotix | $1.4B | 48 |
| IMCR Immunocore Holdings | $1.4B | 51 |
Questions
What is ANAB's stock rating today?
ANAB scores 69/100 (Bullish) as of Nov 19, 2026: technical 55, fundamental 72, and news sentiment 55, which is shown but not counted. Scores are recomputed every night.
What does AnaptysBio do?
AnaptysBio (ANAB), also known as Anaptys, is a royalty company that holds financial interests in medicines developed by larger drug makers. It was formerly an antibody research company, but it spun off its drug development operations into a separate company, First Tracks Biotherapeutics, and kept the royalty assets.
Is ANAB stock a buy?
The score is not a buy or sell recommendation. A 69 says the technical and fundamental signals we measure lean bullish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ANAB score calculated?
98 weighted scorers feed it today: 36 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/anab/"><img src="https://stocksscores.com/stocks/anab/badge.svg" alt="ANAB stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/anab/)